Skip to content
Menu

Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $922

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $875 to $922.

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $875 to $922.

Read at benzinga.com

← All stock news